<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5715">
  <stage>Registered</stage>
  <submitdate>6/01/2015</submitdate>
  <approvaldate>6/01/2015</approvaldate>
  <nctid>NCT02335788</nctid>
  <trial_identification>
    <studytitle>EMBA Peripheral Embolization Device ("EPED") Study</studytitle>
    <scientifictitle>EMBA Peripheral Embolization Device ("EPED") Study</scientifictitle>
    <utrn />
    <trialacronym>EPED</trialacronym>
    <secondaryid>PRT-EPE-0028</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Embolization</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - The EMBA Peripheral Embolization Device

Other: Single arm - EMBA PED - The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.


Treatment: devices: The EMBA Peripheral Embolization Device
arterial and venous embolization in the peripheral vasculature

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Target vessel occlusion (assessed by CTA) - vessel occlusion as assessed by CTA</outcome>
      <timepoint>30 Days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The patient is &gt;18 years of age.

          2. Patient is considered a candidate for arterial or venous embolization in the
             peripheral vasculature.

          3. Patient has a target vessel diameter of 3-8mm and a target PED landing zone of greater
             than 25mm wherein the vessel diameter is between 3 and 8 mm.

          4. The patient or legal guardian has been informed of the nature of the study and agrees
             to its provisions and has provided informed written consent.

          5. The patient has suitable vessel anatomy that would allow proper placement of the PED.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. The patient has one of the following conditions:

             1.1 Arterio-venous fistula 1.2 Hypercoagulability 1.3 Systemic coagulopathy 1.4
             Connective tissue disorder such as Ehlers-Danlos Syndrome 1.5 Congenital arteritis
             such as Takayasu's Disease 1.6 Other circulatory disorders at the discretion of the
             implanting physician

          2. The patient has an uncontrolled infectious disease.

          3. The patient has a life expectancy of less than 6 months.

          4. The patient is pregnant.

          5. The patient has a condition that inhibits radiographic visualization of the PED.

          6. The patient has a known allergy or intolerance to Nitinol.

          7. The patient has a known hypersensitivity to contrast that cannot be pre-treated.

          8. The patient's access vessels preclude safe insertion of the delivery system.

          9. The patient is currently participating in another device or drug study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>EMBA Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open label, acute, non-randomized, prospective, "first in man" (FIM) single-center
      study of the EMBA Medical Peripheral Embolization Device (PED).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02335788</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address />
      <phone>+011 64 (09) 307-4949</phone>
      <fax />
      <email>AndrewH@adhb.govt.nz</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>